ReviewAmerican journal of translational research2015
New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma.
Review in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Clinical significance of miRNA‑1 and its potential target gene network in lung squamous cell carcinoma.Molecular medicine reports · 2019Pooled it
- Using the Precision Lasso for gene selection in diffuse large B cell lymphoma cancer.Journal of the Egyptian National Cancer Institute · 2023Article
- Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma.Oncology letters · 2020Article
- Alkylating anticancer agents and their relations to microRNAs.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Novel prognostic scoring system for diffuse large B-cell lymphoma.Oncology letters · 2018Article
- Survival associated alternative splicing events in diffuse large B-cell lymphoma.American journal of translational research · 2018Article
- Current Progress in EBV-Associated B-Cell Lymphomas.Advances in experimental medicine and biology · 2017Review
- Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer.Journal of Cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B cell lymphoma (DLBCL) accounts for nearly 40% of non-Hodgkin's lymphoma cases. The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refractory to the R-CHOP regimen. Early identification of drug resistance and therapeutic failures are crucial for the identification of high-risk patients. MicroRNAs (miRNAs) are a group of small and non-coding RNAs negatively regulating gene expression through binding to their target mRNAs. Recent studies demonstrated that miRNAs are involved in chemotherapeutic drug resistance in tumor. In our review, we summarize the current evidence on the role of miRNAs in the prediction and modulation of cellular response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone in DLBCL.
Indexed as
Identifiers
26885255PMC4731655W2418653813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.